Drug Trial Radar · NCT03989414
A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)
Last checked: Nov 19, 2026Latest source record: Nov 29, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
424
Planned (sponsor's estimate)
Start
Sep 30, 2019
Primary completion
Nov 30, 2026
Study completion Nov 30, 2026
Sponsor
- Lead sponsor
- CelgeneBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- First posted
- Jun 18, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety and preliminary efficacy of CC-92480 in combination with standard treatments.
Conditions
- Multiple Myeloma
Interventions
CC-92480Drug
Specified dose on specified days
BortezomibDrug
Specified dose on specified days
DexamethasoneDrug
Specified dose on specified days
DaratumumabDrug
Specified dose on specified days
CarfilzomibDrug
Specified dose on specified days
ElotuzumabDrug
Specified dose on specified days
IsatuximabDrug
Specified dose on specified days
CarfilzomibDrug
Specified dose on specified days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Recommended DoseTime frame: Up to approximately 3 years
- Recommended regimen as measured by dose-limiting toxicitiesTime frame: Up to approximately 3 years
- Number of participants with Adverse Events (AEs)Time frame: From first participant first visit until 28 days after the last subject discontinues study treatment, up to 5 years
- Overall response rate (ORR)Time frame: Up to approximately 5 years
Locations
49 sites in 9 countries. Site status is shown where the registry gives one.
Local Institution - 119
Denver, Colorado
Local Institution - 104
Tampa, Florida
Local Institution - 108
Atlanta, Georgia
Local Institution - 112
Chicago, Illinois
Local Institution - 107
Chicago, Illinois
Local Institution - 117
Boston, Massachusetts
Local Institution - 101
Boston, Massachusetts
Local Institution - 118
Boston, Massachusetts
Local Institution - 113
Detroit, Michigan
Local Institution - 106
Rochester, Minnesota
Hackensack University Medical Center
Hackensack, New Jersey
Local Institution - 110
Winston-Salem, North Carolina
Local Institution - 115
Columbus, Ohio
Local Institution - 114
Nashville, Tennessee
Local Institution - 116
Houston, Texas
Swedish Cancer Institute
Seattle, Washington
Local Institution - 201
Calgary, Alberta, Canada
Local Institution - 205
Edmonton, Alberta, Canada
Local Institution - 204
Halifax, Nova Scotia, Canada
Local Institution - 203
Toronto, Ontario, Canada
Local Institution - 202
Montreal, Quebec, Canada
Local Institution - 802
Brno, Czechia
Local Institution - 801
Ostrava-Poruba, Czechia
Local Institution - 803
Prague, Czechia
Local Institution - 902
Odense, Denmark
Local Institution - 903
Vejle, Denmark
Local Institution - 703
Lille, France
Local Institution - 705
Marseille, France
Local Institution - 704
Nantes, France
Local Institution - 701
Toulouse, France
Local Institution - 702
Tours, France
Local Institution - 604
Freiburg im Breisgau, Germany
Local Institution - 605
Hamburg, Germany
Local Institution - 601
Heidelberg, Germany
Local Institution - 602
München, Germany
Local Institution - 603
Würzburg, Germany
Local Institution - 301
Athens, Greece
Local Institution - 404
Brescia, Italy
Local Institution - 401
Milan, Italy
Local Institution - 403
Reggio Emilia, Italy
Showing 40 of 49 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.